Edesa Biotech, Inc. (EDSA) Stock Score, Valuation & Financial Research

Edesa Biotech, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for EDSA

Edesa Biotech, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.72. These figures are a research snapshot, not a buy or sell recommendation.

What Edesa Biotech, Inc. does

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

Company business and revenue

Research reporting period: 2025-09-30. A research update is not a new financial filing.

How the company makes money

Edesa Biotech is a clinical-stage biopharmaceutical company that generates no commercial revenue. Its business model focuses on the research and development of host-directed therapeutics for immuno-inflammatory diseases, funded primarily through equity offerings, government grants, and strategic collaborations.

Products and services

  • The company is developing a pipeline of monoclonal antibody candidates, including paridiprubart (EB05) for Acute Respiratory Distress Syndrome and EB06 for vitiligo.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical-grade drug supplies; specific supplier names are unnamed. Source

Business relationships and partnerships

  • Canadian government’s Strategic Innovation Fund (SIF) — A multi-year contribution agreement for research and development funding. Source

Business strengths to evaluate

  • Intellectual property protection and market exclusivity Source

Business risks and research considerations

  • History of operating losses and need for additional capital Source
  • Dependence on third-party contract manufacturers Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

EDSA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.72
Market capitalization:
35.84M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -14.1M
Free cash flow:
USD -7.32M
Cash:
USD 10.33M
Total debt:
USD 0.00
EPS:
USD -1.69

What stands out

  • Free cash flow is USD -7.32M, negative for the stored period.
  • The balance sheet shows USD 10.33M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 10.33M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for EDSA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can EDSA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is EDSA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for EDSA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of EDSA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research EDSA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.